High-Dimensional Disease Risk Score for Dealing With Residual Confounding Bias in Estimating Treatment Effects With a Survival Outcome.
Saved in:
| Title: | High-Dimensional Disease Risk Score for Dealing With Residual Confounding Bias in Estimating Treatment Effects With a Survival Outcome. |
|---|---|
| Authors: | Hossain MB; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Advancing Health Outcomes, St. Paul's Hospital, Vancouver, British Columbia, Canada., Wong H; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Advancing Health Outcomes, St. Paul's Hospital, Vancouver, British Columbia, Canada., Sadatsafavi M; Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Cook VJ; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Johnston JC; British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.; Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada., Karim ME; School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.; Centre for Advancing Health Outcomes, St. Paul's Hospital, Vancouver, British Columbia, Canada. |
| Source: | Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2025 Jul; Vol. 34 (7), pp. e70172. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 9208369 Publication Model: Print Cited Medium: Internet ISSN: 1099-1557 (Electronic) Linking ISSN: 10538569 NLM ISO Abbreviation: Pharmacoepidemiol Drug Saf Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
